clinical trial · NCT06979323
Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
GlaxoSmithKline·phase3·recruiting·n = 150
AsthmaDepemokimab
brief summary
Asthma is a chronic condition marked by narrowed and swollen airways due to inflammation leading to recurring symptoms that can vary and worsen unpredictably.\\xa0The purpose of this study is to assess how depemokimab, a monoclonal antibody, affects the structure and function of the lungs in asthmatic participants with type 2 inflammation, characterized by an eosinophilic phenotype.
started
Jun 3, 2025
primary completion
Dec 8, 2027
completion
Feb 11, 2028
last updated
Apr 23, 2026
official title
The IMAGINE Study: A Phase 3b Open Label, Single Arm Study to Assess the Effect of Depemokimab on Airway Structure and Function in Asthma With Type 2 Inflammation Characterized by an Eosinophilic Phenotype Utilizing Quantitative High-resolution CT and Bronchoscopic Airway Sampling in a Sub Study
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol